NRx Pharmaceuticals, Inc.
NRXPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NRx Pharmaceuticals, Inc. focuses on Biotechnology services and products. NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic. At a $190.9M market cap, NRx Pharmaceuticals, Inc. ranks as a micro-cap company within healthcare. It operates through NRx and Dura segments.
Market Cap
$190.9M
Beta
2.19
P/E (TTM)
—
P/E (Fwd)
8.92
EPS (TTM)
$-1.04
EPS (Fwd)
$0.50
ROE
—
ROA
-110.2%
Cash
$6.7M
Total Debt
$934,000
Free CF
-$8.5M
52W Change
49.2%
Annual Financials
Cash vs Debt
Where NRXP stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NRXP finished 59.78% above its 150-day moving average ($2.71) and 58.03% above its 200-day moving average ($2.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NRXP overbought or oversold?
At the July 15, 2026 close, NRXP's RSI(14) was 64.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $6.7M in cash comfortably exceeding the $934K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$8.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
A beta of 2.19 means NRXP is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, NRXP has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NRXP.